Interestingly, the GHRH antagonist MZ-5-516 in prostate cancer cells [66], as well as MIA-602, MIA-606 and MIA-690 in non-small cell lung cancer cells [67], reduced VEGF secretion and attenuated the mRNA expression and activity of MMP2 and MMP9. Here, MMP2 is linked to prostate cancer.